Amgen Inc (AMGN34 SA) stock market data APIs
R$65.866
0(0%)
as of March 24, 2026
Try our APIs with
free plan!
Amgen Inc Financial Data Overview
Price chart is built with
Anychart
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Prev. Close
65.866
Open
65.866
High
65.866
Low
65.866
52 wk Range
48.1618-77.7857
Market Cap
988 197 M
P/E Ratio
24.6128
Shares Outstanding
15 094 M
Revenue
36 751 M
Dividends (Yield)
0.1454
Beta
0.425
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amgen Inc data using free add-ons & libraries
Get Amgen Inc Fundamental Data
Amgen Inc Fundamental data includes:
- Net Revenue: 36 751 M
- EBITDA: 16 617 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amgen Inc News
New
Assessing Amgen (AMGN) Valuation After Recent Share Price Pullback And Mixed Short Term Returns
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (AMGN) is back in focus after recent trading, with the share price closing at US$348....
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
Johnson & Johnson’s JNJ stock has remained firmly above its 50-day and 200-day simple moving averages (SMAs) for more than eight months, dating back to mid-July 2025, reflecting sustained investor c...
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
Bristol Myers BMY recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with active psoriatic arthritis (PsA). The decision adds a second major indicati...
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?
Amgen AMGN stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January. The 50-day moving average is a short-term indicator, while the 200-day m...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
